A Phase I Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2016
At a glance
- Drugs Golvatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Apr 2012 Planned end date changed from 1 Aug 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 07 Apr 2009 New trial record